Answers are grounded in this paper and cite their sources.
Merck & Co. has agreed to buy the ophthalmology firm EyeBio for $1.3 billion up front and up to $1.7 billion in milestone payments. Once the deal closes, Merck will inherit a trispecific antibody called Restoret, which EyeBio is developing as a treatment for vision loss caused by diabetic macular edema and neovascular age-related macular degeneration. Restoret is in early-stage human trials.
No takes yet. Share an insight, caveat, or question.
Rowan Walrath (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: